Learn
Research-backed guides on CBD pharmacology, medication safety, and condition-specific evidence. Every article cites primary literature โ PubMed where available.
GLP-1 medications
Semaglutide and tirzepatide cause real changes in joint loading and lean mass. These guides cite the primary literature โ including a widely-cited RCT that was retracted โ and say plainly where the evidence runs out.
CBD inhibits CYP3A4, CYP2C9, CYP2C19, CYP2D6, and UGT enzymes, the same pathways that clear most prescription medications. Per-drug evidence, severity ratings, and prescriber questions.
Warfarin
INR monitoring required
Benzodiazepines
Geffrey 2015: clobazam +60%, N-CLB +500%
SSRIs
Anderson 2022: CYP2D6 pharmacogenomics matter
Statins
CYP3A4, simvastatin / atorvastatin highest risk
Blood pressure medications
CYP3A4 + direct BP-lowering signal (Jadoon 2017)
Plaquenil (hydroxychloroquine)
CYP2D6 + CYP3A4 dual pathway
NSAIDs
OTC occasional: low risk; chronic Rx: discuss with prescriber
Levothyroxine
Absorption timing; TSH monitoring on long-term CBD
Gabapentin
Not CYP-mediated; additive sedation is the concern
Tylenol (acetaminophen)
UGT overlap + AM404; chronic high-dose use warrants awareness
CYP450 mechanism explainer
How enzyme inhibition works, plain English
What the research says, and doesn't say, about CBD for specific autoimmune and inflammatory conditions. Honest evidence framing; no therapeutic claims.
Hashimoto's thyroiditis
No clinical trials for Hashimoto + CBD; ECS mechanism and safety context
Psoriatic arthritis
Vela 2022 RCT: null result for PsA specifically; honest framing
Ankylosing spondylitis
No AS-specific CBD trial; IL-17/IL-23 axis + Fitzcharles 2016 survey context
Hip osteoarthritis
Pramhas 2023 was knee-specific; topical CBD cannot reach hip joint
How-to guides
Practical protocols for using CBD safely and effectively.
CBD and joint pain: evidence by condition, topical vs oral, medication safety
Pillar hub, Pramhas 2023 RCT anchor; Vela 2022 null; 6 condition evidence table
Inflammaging and CBD: the Franceschi framework and what the evidence supports
Franceschi 2018 framework; NF-ฮบB/Nrf2/CB2; honest 'no human RCT' disclosure
CBD and inflammation: the mechanism explainer
NF-ฮบB, CB2, Th1/Th17, FAAH, preclinical strong, human evidence condition-specific
CBD and chronic pain: what the evidence actually shows
Pain type framework: nociceptive, neuropathic, nociplastic, Pramhas 2023 + Mucke 2018
CBD science & dosing: how it works, bioavailability, and dosing
ECS, FAAH, inverted-U dose-response (Linares 2019), food effect (Birnbaum 2019 4โ5ร)
CBD dosing for autoimmune conditions
Start at 10mg, not 25mg, drug interactions come first
CBD for sleep and stress: pillar hub
Shannon 2019 + Bergamaschi 2011; 5-HT1A not GABA-A; cortisol/HPA axis bridge
CBD and sleep
Shannon 2019 n=72: continuity over initiation; not a sedative
CBD and anxiety
Bergamaschi 2011 RCT + Shannon 2019: acute model stronger than chronic GAD
CBD titration protocol
General start low, go slow protocol, Linares 2019
How to read a CBD certificate of analysis
Potency, pesticides, heavy metals, and what to look for
CBD for masters athletes
Recovery, inflammation, and WADA compliance